GB2619410A - Methods and compositions for cellular therapy - Google Patents
Methods and compositions for cellular therapy Download PDFInfo
- Publication number
- GB2619410A GB2619410A GB2306292.0A GB202306292A GB2619410A GB 2619410 A GB2619410 A GB 2619410A GB 202306292 A GB202306292 A GB 202306292A GB 2619410 A GB2619410 A GB 2619410A
- Authority
- GB
- United Kingdom
- Prior art keywords
- complex
- nucleic acid
- acid molecule
- sequence
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract 18
- 238000002659 cell therapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 claims abstract 76
- 102000039446 nucleic acids Human genes 0.000 claims abstract 76
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 76
- 239000000427 antigen Substances 0.000 claims abstract 7
- 108091007433 antigens Proteins 0.000 claims abstract 7
- 102000036639 antigens Human genes 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 210000000265 leukocyte Anatomy 0.000 claims abstract 6
- 201000010099 disease Diseases 0.000 claims abstract 5
- 210000000130 stem cell Anatomy 0.000 claims abstract 4
- 230000028993 immune response Effects 0.000 claims abstract 3
- 208000035475 disorder Diseases 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 49
- 210000001744 T-lymphocyte Anatomy 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 17
- 102000002698 KIR Receptors Human genes 0.000 claims 14
- 108010043610 KIR Receptors Proteins 0.000 claims 14
- 125000000539 amino acid group Chemical group 0.000 claims 14
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 12
- 108010075704 HLA-A Antigens Proteins 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 10
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 10
- 108010058607 HLA-B Antigens Proteins 0.000 claims 10
- 108010052199 HLA-C Antigens Proteins 0.000 claims 10
- 230000005867 T cell response Effects 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 230000006337 proteolytic cleavage Effects 0.000 claims 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 5
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 5
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 4
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 claims 4
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 4
- 108010024164 HLA-G Antigens Proteins 0.000 claims 4
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 4
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- 101710185679 CD276 antigen Proteins 0.000 claims 2
- 102100036008 CD48 antigen Human genes 0.000 claims 2
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000983747 Homo sapiens MHC class II transactivator Proteins 0.000 claims 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 2
- 102100026371 MHC class II transactivator Human genes 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims 2
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000004154 complement system Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims 1
- -1 N0X2 Proteins 0.000 claims 1
- 108010082739 NADPH Oxidase 2 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2016659.1A GB202016659D0 (en) | 2020-10-20 | 2020-10-20 | Methods and compositions for cellular therapy |
| GBGB2101665.4A GB202101665D0 (en) | 2021-02-05 | 2021-02-05 | Methods and compositions for cellular therapy |
| PCT/US2021/055682 WO2022087019A1 (en) | 2020-10-20 | 2021-10-19 | Methods and compositions for cellular therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202306292D0 GB202306292D0 (en) | 2023-06-14 |
| GB2619410A true GB2619410A (en) | 2023-12-06 |
Family
ID=81290046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2306292.0A Pending GB2619410A (en) | 2020-10-20 | 2021-10-19 | Methods and compositions for cellular therapy |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240124551A1 (https=) |
| EP (1) | EP4232468A4 (https=) |
| JP (1) | JP2023546300A (https=) |
| KR (1) | KR20230110258A (https=) |
| AU (1) | AU2021364550A1 (https=) |
| CA (1) | CA3196346A1 (https=) |
| GB (1) | GB2619410A (https=) |
| WO (1) | WO2022087019A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102776627B1 (ko) | 2019-05-06 | 2025-03-06 | 토마스 말콤 | 암 종양에 대한 맞춤화된 하이포면역 나노소포체 전달 시스템 |
| GB202205771D0 (en) * | 2022-04-20 | 2022-06-01 | Replay Holdings Llc | Methods and compositions for cellular therapy |
| GB202316281D0 (en) * | 2023-10-24 | 2023-12-06 | Replay Holdings Inc | Methods and compositions for modulating immune cell activity in cellular therapy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9765330B1 (en) * | 2015-01-09 | 2017-09-19 | Nant Holdings Ip, Llc | Compositions and methods for reduction of allograft recognition and rejection |
| WO2018132783A1 (en) * | 2017-01-13 | 2018-07-19 | The Regents Of The University Of California | Immunoengineered pluripotent cells |
| WO2020012033A1 (en) * | 2018-07-13 | 2020-01-16 | Lothar Germeroth | Non-immunogenic engineered tissue and methods of producing and using the same |
| WO2020013734A1 (ru) * | 2018-07-10 | 2020-01-16 | Общество С Ограниченной Ответственностью "Бетарут" | Способ и устройство жидкой ковки двойного действия |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10503379A (ja) * | 1994-07-29 | 1998-03-31 | デイド・インターナショナル・インコーポレーテッド | Ｍｈｃ複合体およびその用途 |
| US6211342B1 (en) * | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| GB0107628D0 (en) * | 2001-03-27 | 2001-05-16 | Avidex Ltd | Substances |
| GB0115071D0 (en) * | 2001-06-20 | 2001-08-15 | Avidex Ltd | Substances |
| US8895020B2 (en) * | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| WO2018089661A1 (en) * | 2016-11-09 | 2018-05-17 | La Jolla Institute For Allergy And Immunology | Use of c-terminally extended peptides to disrupt inhibitor nk cell receptor interactions with mhc i |
| WO2020051373A1 (en) * | 2018-09-06 | 2020-03-12 | Optumsoft, Inc. | Automatic generation of an efficient rule set implementation |
-
2021
- 2021-10-19 EP EP21883739.1A patent/EP4232468A4/en active Pending
- 2021-10-19 CA CA3196346A patent/CA3196346A1/en active Pending
- 2021-10-19 GB GB2306292.0A patent/GB2619410A/en active Pending
- 2021-10-19 JP JP2023548545A patent/JP2023546300A/ja active Pending
- 2021-10-19 KR KR1020237016408A patent/KR20230110258A/ko not_active Withdrawn
- 2021-10-19 WO PCT/US2021/055682 patent/WO2022087019A1/en not_active Ceased
- 2021-10-19 AU AU2021364550A patent/AU2021364550A1/en not_active Abandoned
-
2023
- 2023-04-19 US US18/303,075 patent/US20240124551A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9765330B1 (en) * | 2015-01-09 | 2017-09-19 | Nant Holdings Ip, Llc | Compositions and methods for reduction of allograft recognition and rejection |
| WO2018132783A1 (en) * | 2017-01-13 | 2018-07-19 | The Regents Of The University Of California | Immunoengineered pluripotent cells |
| WO2020013734A1 (ru) * | 2018-07-10 | 2020-01-16 | Общество С Ограниченной Ответственностью "Бетарут" | Способ и устройство жидкой ковки двойного действия |
| WO2020012033A1 (en) * | 2018-07-13 | 2020-01-16 | Lothar Germeroth | Non-immunogenic engineered tissue and methods of producing and using the same |
Non-Patent Citations (4)
| Title |
|---|
| FAVIER, B. et al., "Tolerogenic Function of Dimeric Forms of HLA-G Recombinant Proteins: A Comparative Study In Vivo", PLoS ONE,2011, vol. 6, no. 7, e21011 doi:10.1371/journal.pone.0021011, Abstract, Figure 1 * |
| Fodor James et al."Previously Hidden Dynamics at the TCR-Peptide-MHC Interface Revealed", The Journal of Immunology, 2018, vol. 200, pages 4134 - 4145, The whole document, in particular Table 1, Figures 1-7 and page 4138 * |
| GORNALUSSE G.G. et al., "HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells", Nature Biotechnology,2017, vol. 35, no. 8, pages 765 - 772, * |
| Shi Lei, Li et al. "Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted (32m-HLA-G fusion proteins", Stem Cells, 2020, vol. 38, pages 1423 - 1437, Abstract, page 1424 * * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021364550A9 (en) | 2025-03-13 |
| KR20230110258A (ko) | 2023-07-21 |
| EP4232468A1 (en) | 2023-08-30 |
| EP4232468A4 (en) | 2025-03-19 |
| US20240124551A1 (en) | 2024-04-18 |
| AU2021364550A1 (en) | 2023-06-08 |
| GB202306292D0 (en) | 2023-06-14 |
| JP2023546300A (ja) | 2023-11-01 |
| WO2022087019A1 (en) | 2022-04-28 |
| CA3196346A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2619410A (en) | Methods and compositions for cellular therapy | |
| JP2021521776A5 (https=) | ||
| Wooldridge et al. | Tricks with tetramers: how to get the most from multimeric peptide–MHC | |
| IL272085B2 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| Simpson et al. | Minor histocompatibility antigens | |
| van den Elsen et al. | Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-γ inducible promoter (PIV) of CIITA | |
| JP2021500855A5 (https=) | ||
| EP2730588A1 (en) | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof | |
| AU2016363025A1 (en) | Modified chimeric receptors and related compositions and methods | |
| JP2024105344A (ja) | 多量体ｔ細胞調節ポリペプチド及びその使用方法 | |
| US20200297760A1 (en) | Compositions and methods for reducing immune responses against chimeric antigen receptors | |
| CA3113100A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JPWO2019204683A5 (https=) | ||
| Pietra et al. | HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells | |
| US20240376177A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JPWO2021055594A5 (https=) | ||
| JPWO2022178367A5 (https=) | ||
| JP2025540733A (ja) | マイナー組織適合抗原ｈａ－２を標的とするｔ細胞受容体 | |
| Blanchard et al. | The role of the T cell receptor, CD8, and LFA-1 in different stages of the cytolytic reaction mediated by alloreactive T lymphocyte clones. | |
| Früh et al. | Targeting MHC-E as a new strategy for vaccines and immunotherapeutics | |
| JPWO2020132138A5 (https=) | ||
| Coccoris et al. | Prospects and limitations of T cell receptor gene therapy | |
| JPWO2020257191A5 (https=) | ||
| CA2123303C (en) | Icams immunoglobulin constant region soluble fusion proteins | |
| O'Callaghan | Natural killer cell surveillance of intracellular antigen processing pathways mediated by recognition of HLA-E and Qa-1b by CD94/NKG2 receptors |